Nanologica has recruited Ulf Ericsson as VP Drug Development as part of the strategy to enhance focus on the respiratory field and inhalation, within the business area Drug Development. Mr. Ericsson will be responsible for leading the work on developing inhalable pharmaceuticals. To accelerate the development of the NLAB Spiro® inhalation platform, Ulf Ericsson has been recruited as VP Drug Development. The position includes leading efforts and strategy for the development and commercialization of the platform. Mr. Ericsson also has an extensive experience in insight-driven brand strategy development and implementation, as well as in forecasting, evaluation, and business case development. His appointment is effective as of September 1, 2021.